Auris Medical Holding to Present at the 13th Annual LD Micro Main Event Conference
December 07 2020 - 4:10PM
Hamilton, Bermuda, December 7, 2020 – Auris
Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company
dedicated to developing therapeutics that address important unmet
medical needs in neurotology, rhinology and allergy and CNS
disorders, today announced that Chairman and CEO Thomas Meyer will
present at the 13th Annual LD Micro Main Event investor conference
on Tuesday, December 15, 2020, at 10:40 a.m. EST. The event will be
webcast live and available via the event homepage
https://ve.mysequire.com/.
About Auris Medical
Auris Medical is a clinical-stage company
dedicated to developing therapeutics that address important unmet
medical needs in neurotology, rhinology and allergy and CNS
disorders. The Company is focused on the development of intranasal
betahistine for the treatment of vertigo (AM-125, in Phase 2) and
for the prevention of antipsychotic-induced weight gain and
somnolence (AM-201, post Phase 1b). Through its affiliate Altamira
Medica, the Company is developing a nasal spray for protection
against airborne pathogens and allergens (AM-301). In addition,
Auris Medical has two Phase 3 programs under development: Sonsuvi®
(AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101)
for acute inner ear tinnitus. The Company was founded in 2003 and
is headquartered in Hamilton, Bermuda with its main operations in
Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade
on the NASDAQ Capital Market under the symbol “EARS.”
Investor contact:
investors@aurismedical.com
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Sep 2023 to Sep 2024